Compare Abeona Therapeutics Inc (ABEO) vs AGNC Investment Corp (AGNC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs AGNC Investment Corp — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while AGNC Investment Corp trades at $10.99 (market cap $12.76B). The key difference: AGNC Investment Corp is far larger — about 34.2× Abeona Therapeutics Inc's market cap, and AGNC Investment Corp pays a 12.95% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AGNC | |
|---|---|---|
Market Cap | $373.32M | $12.76B |
Sector | Health | Financials |
52-Week High | $7.23 | $12.17 |
52-Week Low | $4.17 | $9.20 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 12.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AGNC trades at $11.12, up 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $11.33. The stock shows strong profitability with a net income margin of 91.71% and ROE of 13.98%, though recent earnings have been mixed with a Q1 2026 beat but misses in prior quarters. Dividend payments of $0.12 per share continue regularly, supporting income-focused investors amid interest rate sensitivity concerns highlighted in recent news.
Outlook remains cautiously optimistic given analyst buy ratings (37.14%) and technical momentum, but risks include Federal Reserve policy shifts impacting mortgage-backed securities and earnings volatility. The stock's valuation at P/E 8.73 and P/B 1.26 offers relative value, though investors must monitor interest rate trends for dividend sustainability and book value stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →
